Work

Sat0400 Real-world Switch Rates Among Biologic-naive Psoriatic Arthritis Patients Initiating Apremilast, Tumor Necrosis Factor Inhibitors or Interleukin Inhibitors

Year: 2019

Type: article

Study design: Observational Study

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2019-eular.1984

Authors: David Kaplan, Brian Ung, Corey Pelletier, Chuka Udeze, Marc Tian

Institutions: Adult and Pediatric Dermatology, Celgene (United States)

Language: English

Topic: Spondyloarthritis Studies and Treatments

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Sanofi, Celgene, Novartis Pharma, Chugai Pharmaceutical

OpenAlex ID: W2951767243

FWCI: 0.329

Cites: 1

Cited by: 2

Related to: 10